Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients ...

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.

The NIH is considering a catastrophic cut to indirect cost reimbursements for public universities, which would hurt the ...

Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 weeks compared with sham in patients aged 2 to 18 years with spinal muscular ...

Girl from Bengal's Nadia suffers from spinal muscular atrophy Rs 1.4 crore still needed for girl's treatment which costs Rs 17 crore Suvendu Adhikari urges others to donate towards girl's treatment ...

Patients in Scotland can't get the treatment - which is available in England - despite manufacturers giving it away for free ...

The Supreme Court has sought a response from the maker of Risdiplam on why the spinal muscular atrophy drug is priced lower ...

Nearly six years ago, the Food and Drug Administration approved Zolgensma, a Novartis gene therapy for the fatal neuron-wasting disease spinal muscular atrophy. It heralded a new era of genetic ...

Niagara SPCA has rescued a snake named Poly, suffering from severe health issues, and placed her in experienced foster care ...